Materials and Methods: This randomized clinical trial included 70 patients with a diagnosis of PCOS according to the Rotterdam criteria. The samples were selected from patients referred to a specialty clinic in Mashhad, Iran from 2017 to 2018R. Patients were randomly assigned into two groups of intervention and control. While the intervention group received two chamomile capsules (500 mg) daily for three months, the control group received two placebo capsules daily for three months. Both groups underwent ultrasounds on days 3 and 12 of the first and third cycles. The collected data were analyzed using SPSS software version 20.

Results: The mean age of patients in the control and intervention groups was 28.06 ± 5.71 and 25.43 ± 5.58 years, respectively. There was no significant difference between the two groups in terms of age and body mass index (BMI) before treatment. Ovarian volume on day 12 of the third cycle was significantly lower in the intervention group (P = 0.01). The number of dominant follicles in the intervention group was significantly higher after treatment (P = 0.02). While hirsutism improved in the chamomile group (P = 0.028), there was no significant difference between the two groups in terms of testosterone levels (P = 0.894).

Conclusions: According to our results, chamomile treatment regimen could increase the dominant follicle, and thus affect the induction of ovulation in patients with PCOS.